TY - JOUR
T1 - Efficacy and safety of antipsychotic treatments for schizophrenia
T2 - A systematic review and network meta-analysis of randomized trials in Japan
AU - Kishi, Taro
AU - Ikuta, Toshikazu
AU - Sakuma, Kenji
AU - Okuya, Makoto
AU - Iwata, Nakao
N1 - Funding Information:
This work was supported by MEXT/JSPS KAKENHI Grant Number JP19K08082 . We thank Dr. Kenji Sanada (Showa University School of Medicine, Japan), Dr. Hikaru Hori (University of Occupational and Environmental Health, Kitakyushu, Japan), Prof. Reiji Yoshimura (University of Occupational and Environmental Health, Japan), Dr. Hiroko Yanagimoto (Kurume University, Japan), Prof. Kiichiro Morita(Kurume University, Japan), Prof. Yoshihisa Shoji (Kurume University, Japan), Dr. Kotaro Hatta (Juntendo University Nerima Hospital, Japan), Prof. Takefumi Suzuki (Faculty of Medicine, University of Yamanashi, Japan), Dr. Takuya Ishizuka (Hasegawa Hospital, Japan), Dr. Hidehisa Yamashita (Graduate School of Biomedical Sciences Hiroshima University, Japan), Dr. Goro Sato (Graduate School of Biomedical Sciences Hiroshima University, Japan), Dr. Gaku Okugawa (Kansai Medical University, Japan), Dr. Yoshiteru Takekita (Kansai Medical University, Japan), Sumitomo Dainippon Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K, Astellas Pharma Inc., AstraZeneca plc, Eli Lilly and Company, and Meiji Seika Pharma Co., Ltd. for providing the unpublished information about their studies.
Funding Information:
Dr. Kishi received speaker's honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Janssen, Otsuka, Meiji, Mochida, MSD, and Tanabe-Mitsubishi (Yoshitomi), as well as research grants from the Japanese Ministry of Health, Labour, and Welfare (H29-Seishin-Ippan-001, 19GC1012), MEXT/JSPS KAKENHI Grant Number JP19K08082, and Fujita Health University School of Medicine.
Funding Information:
This work was supported by MEXT/JSPS KAKENHI Grant Number JP19K08082. We thank Dr. Kenji Sanada (Showa University School of Medicine, Japan), Dr. Hikaru Hori (University of Occupational and Environmental Health, Kitakyushu, Japan), Prof. Reiji Yoshimura (University of Occupational and Environmental Health, Japan), Dr. Hiroko Yanagimoto (Kurume University, Japan), Prof. Kiichiro Morita(Kurume University, Japan), Prof. Yoshihisa Shoji (Kurume University, Japan), Dr. Kotaro Hatta (Juntendo University Nerima Hospital, Japan), Prof. Takefumi Suzuki (Faculty of Medicine, University of Yamanashi, Japan), Dr. Takuya Ishizuka (Hasegawa Hospital, Japan), Dr. Hidehisa Yamashita (Graduate School of Biomedical Sciences Hiroshima University, Japan), Dr. Goro Sato (Graduate School of Biomedical Sciences Hiroshima University, Japan), Dr. Gaku Okugawa (Kansai Medical University, Japan), Dr. Yoshiteru Takekita (Kansai Medical University, Japan), Sumitomo Dainippon Pharma Co. Ltd. Otsuka Pharmaceutical Co. Ltd. Janssen Pharmaceutical K.K, Astellas Pharma Inc. AstraZeneca plc, Eli Lilly and Company, and Meiji Seika Pharma Co. Ltd. for providing the unpublished information about their studies.
Funding Information:
Dr. Sakuma has received speaker's honoraria from Eisai, Kissei, Meiji, Otsuka, and Torii and has received a Fujita Health University School of Medicine research grant, as well as a MEXT/JSPS KAKENHI Grant Young Scientis (B).
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/6
Y1 - 2021/6
N2 - Background: We examined the efficacy and safety of using antipsychotic medication for schizophrenia using only randomized trials of antipsychotic for schizophrenia conducted in Japan to avoid the biological and environmental heterogeneities caused by pooling data from various races and ethnicities. Methods: We searched for eligible studies on Embase, PubMed, and CENTRAL. Primary outcomes were improvement in Positive and Negative Syndrome Scale total score (PANSS−T) and all-cause discontinuation. Other outcomes were improvement in PANSS subscale scores, discontinuation due to adverse events or inefficacy, and the incidence of 16 adverse events. Results: We calculated mean difference or risk ratios and 95% credible intervals. We identified 34 RCTs (6798 patients; mean study duration, 9.0 ± 4.24 weeks; proportion of male patients, 53.7%; mean age, 43.3 years). Besides placebo, studies included aripiprazole, asenapine, blonanserin, blonanserin-patch, brexpiprazole, clocapramine (no PANSS data), clozapine (no PANSS data), haloperidol, lurasidone, mosapramine, olanzapine, paliperidone, perospirone, quetiapine, and risperidone. Efficacy and safety profiles differed for antipsychotics used with schizophrenia in Japanese patients. All active treatments other than haloperidol and quetiapine outperformed placebo to improve PANSS−T. Asenapine, olanzapine, paliperidone, and risperidone outperformed placebo for all-cause discontinuation. Asenapine, blonanserin, blonanserin-patch, haloperidol, lurasidone, mosapramine, olanzapine, paliperidone, and risperidone outperformed placebo to improve PANSS positive subscale scores. Aripiprazole, asenapine, blonanserin, blonanserin-patch, brexpiprazole, lurasidone, olanzapine, paliperidone, perospirone, and risperidone outperformed placebo to improve PANSS negative subscale scores. The confidence in evidence of most outcomes was low or very low. Conclusion: Our results are similar to those of previous network meta-analysis involving various races and ethnicities.
AB - Background: We examined the efficacy and safety of using antipsychotic medication for schizophrenia using only randomized trials of antipsychotic for schizophrenia conducted in Japan to avoid the biological and environmental heterogeneities caused by pooling data from various races and ethnicities. Methods: We searched for eligible studies on Embase, PubMed, and CENTRAL. Primary outcomes were improvement in Positive and Negative Syndrome Scale total score (PANSS−T) and all-cause discontinuation. Other outcomes were improvement in PANSS subscale scores, discontinuation due to adverse events or inefficacy, and the incidence of 16 adverse events. Results: We calculated mean difference or risk ratios and 95% credible intervals. We identified 34 RCTs (6798 patients; mean study duration, 9.0 ± 4.24 weeks; proportion of male patients, 53.7%; mean age, 43.3 years). Besides placebo, studies included aripiprazole, asenapine, blonanserin, blonanserin-patch, brexpiprazole, clocapramine (no PANSS data), clozapine (no PANSS data), haloperidol, lurasidone, mosapramine, olanzapine, paliperidone, perospirone, quetiapine, and risperidone. Efficacy and safety profiles differed for antipsychotics used with schizophrenia in Japanese patients. All active treatments other than haloperidol and quetiapine outperformed placebo to improve PANSS−T. Asenapine, olanzapine, paliperidone, and risperidone outperformed placebo for all-cause discontinuation. Asenapine, blonanserin, blonanserin-patch, haloperidol, lurasidone, mosapramine, olanzapine, paliperidone, and risperidone outperformed placebo to improve PANSS positive subscale scores. Aripiprazole, asenapine, blonanserin, blonanserin-patch, brexpiprazole, lurasidone, olanzapine, paliperidone, perospirone, and risperidone outperformed placebo to improve PANSS negative subscale scores. The confidence in evidence of most outcomes was low or very low. Conclusion: Our results are similar to those of previous network meta-analysis involving various races and ethnicities.
UR - http://www.scopus.com/inward/record.url?scp=85105357222&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105357222&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychires.2021.04.032
DO - 10.1016/j.jpsychires.2021.04.032
M3 - Article
C2 - 33964682
AN - SCOPUS:85105357222
SN - 0022-3956
VL - 138
SP - 444
EP - 452
JO - Journal of Psychiatric Research
JF - Journal of Psychiatric Research
ER -